StocksInsight

INSM Stock vs the S&P 500: Returns, Risk and Crash History

Insmed Incorporated, healthcare (market value $22.9 billion): how it compared with the S&P 500, how it behaved in every crash since 2008, its risk‑adjusted returns and what analysts said. Returns to Oct 30, 2026; analyst data as of Nov 16, 2026.

Published Updated 4 min readHow we research

What changed since Nov 9

Exent re-checks this page every day. Ratings appear 30 days after they are published; the top‑ranked analysts’ calls are not counted here, they are in Gems.

+1 new rating96% Buy ratings (was 100%)24 analysts covering (was 23)11 4★+ analysts covering (was 10)

Key takeaways

  • INSM returned +273.4% over the 5 years to Oct 30, 2026 versus +75.9% for the S&P 500: it beat the index.
  • Its 5-year Sharpe ratio was 0.58 against 0.58 for the S&P 500.
  • Its deepest crisis drawdown was −66.4% in the global financial crisis (2007–09) (S&P 500: −56.5%).
  • Five‑year volatility was 60.5% and beta 0.84.
  • 24 analysts rated it in the past year; 96% of their latest calls were Buy.
  • INSM beat earnings estimates in 3 of its last 12 reports; the stock moved 8.9% on average, up or down, around each report.

What do the best‑ranked analysts on INSM say now? See it in Exent Gems →

Did INSM beat the S&P 500?

Over the 5 years to Oct 30, 2026, Insmed Incorporated (INSM) returned +273.4% including dividends, versus +75.9% for the S&P 500 (SPY). It beat the index by 197.5 percentage points, or +30.1% a year against +12.0%.

PeriodINSMS&P 500INSM per yearS&P 500 per yearResult
1 year−40.6%+12.0%−40.6%+12.0%Lagged
3 years+349.2%+87.4%+65.0%+23.3%Beat
5 years+273.4%+75.9%+30.1%+12.0%Beat
10 years+767.3%+316.3%+24.1%+15.3%Beat
  • 1 year
    INSM
    −40.6%
    S&P 500
    +12.0%
    INSM per year
    −40.6%
    S&P 500 per year
    +12.0%
    Result
    Lagged
  • 3 years
    INSM
    +349.2%
    S&P 500
    +87.4%
    INSM per year
    +65.0%
    S&P 500 per year
    +23.3%
    Result
    Beat
  • 5 years
    INSM
    +273.4%
    S&P 500
    +75.9%
    INSM per year
    +30.1%
    S&P 500 per year
    +12.0%
    Result
    Beat
  • 10 years
    INSM
    +767.3%
    S&P 500
    +316.3%
    INSM per year
    +24.1%
    S&P 500 per year
    +15.3%
    Result
    Beat

Total return with dividends reinvested, from month-end prices to Oct 30, 2026. Beating the index on raw return is only half the story: the next section adjusts for the risk taken. See also how to beat the S&P 500.

What Wall Street analysts say about INSM

In the 12 months to 30 days ago, 24 analysts published 393 ratings on INSM. Their latest calls were 96% Buy, 4% Hold and 0% Sell. 11 of them rank 4★ or higher in Exent’s analyst scoring, which is based on each analyst’s past price‑target hit rate and returns.

The consensus 12‑month price target was $191.06 (range $154.00–$235.00), +59.5% from the last price. Remember that the average analyst’s target is hit only about half the time: how accurate are price targets?

Top‑ranked analyst coveringFirmStarsPrice‑target hit rate
Faisal KhurshidJefferies5.0★51.7%
Ritu BaralTD Cowen5.0★41.0%
??????4.9★51.4%
??????4.9★27.9%
Vamil DivanGuggenheim4.9★47.7%

Other analysts covering INSM: Maxwell Skor · Jessica Fye · Graig Suvannavejh · Jason Zemansky · Leonid Timashev · Danielle Brill

Ratings are shown with a 30‑day delay. Who the top‑ranked analysts on INSM are, their live calls and the median target of only the top‑rated analysts are in Exent Gems.

The average analyst’s target is reached about 53.0% of the time; Exent Gems is built on the top 50 of Exent’s ranking,where some reached 90% or more over the last two years. Unlock the top 50 analysts.

INSM returns by year vs the S&P 500

INSM beat the S&P 500 in 6 of the 9 full calendar years shown.

YearINSMS&P 500Difference
2026 (to Oct 30, 2026)−35.3%+11.7%−47.0%
2025+152.1%+17.7%+134.4%
2024+122.8%+24.9%+97.9%
2023+55.1%+26.2%+28.9%
2022−26.7%−18.2%−8.5%
2021−18.2%+28.7%−46.9%
2020+39.4%+18.3%+21.1%
2019+82.0%+31.2%+50.8%
2018−57.9%−4.6%−53.3%
2017+135.7%+21.7%+114.0%

INSM risk-adjusted returns: Sharpe, Sortino and volatility

Over 5 years, INSM had a Sharpe ratio of 0.58 against 0.58 for the S&P 500, so it earned less return per unit of risk than the index. Its annualized volatility was 70.4% and its beta 0.84: it tended to move about 0.8× as much as the market.

MetricINSMS&P 500
Annual return+30.1%+12.0%
Volatility (annualized)70.4%15.5%
Sharpe ratio0.580.58
Sortino ratio1.600.91
Max drawdown (month-end)−52.5%−23.9%
Beta to the S&P 5000.841.00

Sharpe divides return above cash by total volatility; Sortino counts only downside volatility. Both use monthly returns and the 1–3 month T‑bill ETF (BIL) as the risk‑free rate.

How INSM behaved in past crashes

INSM’s deepest fall in the crises below was −66.4% in the global financial crisis (2007–09), against −56.5% for the S&P 500. The last column turns that into money: what a $100,000 position would have lost from peak to trough.

CrisisINSMS&P 500Loss on $100,000
Global financial crisis (2007–09)−66.4%−56.5%−$66,360
2018 trade-war selloff−48.4%−20.2%−$48,420
COVID crash (Feb–Mar 2020)−56.4%−34.1%−$56,380
2022 inflation bear market−39.3%−25.4%−$39,320
2025 tariff selloff−22.5%−19.0%−$22,500
WindowINSM max drawdown
Last 1 year−52.1%
Last 3 years−52.1%
Last 5 years−52.1%
Last 10 years−64.8%

Peak‑to‑trough declines from daily prices inside each crisis window. A crash replay does not predict the next crisis; it shows how much room a holding needs. Run the same replay on a whole portfolio with the crash test.

What moves with INSM, and what doesn’t

Correlation runs from −1 (moves opposite) to +1 (moves in lockstep). Over the last 60 months of monthly returns, INSM’s correlation with the S&P 500 was 0.18, with the Nasdaq‑100 0.16, with long Treasuries (TLT) 0.30 and with gold (GLD) 0.06.

Adding a 5% INSM position to an S&P 500 portfolio would have moved its 5‑year volatility from 15.5% to 15.7%.

Least correlated large capsCorrelationMost correlated large capsCorrelation
MNST−0.17NEE0.32
FTNT−0.15COST0.27
LMT−0.13PLD0.26
MCD−0.13MCO0.25
BMY−0.11HWM0.25

Holdings that are highly correlated behave like one position in a selloff. See how to find hidden overlap.

Latest INSM upgrades, downgrades and price‑target changes

DateRating and targetAnalyst
Nov 3Target raised
Buy
Target $158, was $154
Graig Suvannavejh
Mizuho Securities
Nov 1Target cut
Buy
Target $201, was $205
Vamil Divan
Guggenheim
Oct 29Target cut
Buy
Target $154, was $195
Graig Suvannavejh
Mizuho Securities
Oct 21Target cut
Buy
Target $213, was $218
Maxwell Skor
Morgan Stanley
Oct 20Target cut
Buy
Target $173, was $185
Tiago Fauth
Raymond James
Oct 12Target cut
Buy
Target $207, was $214
Jason Zemansky
Bank of America Securities
Oct 12Downgrade
Hold
Andy Chen
Wolfe Research
Sep 30Target cut
Buy
Target $207, was $237
Eliana Merle
Barclays
Sep 24New coverage
Buy
Target $188, was $230
Andrea Newkirk
Goldman Sachs

Named analysts’ rating and price‑target changes on INSM in the 5 weeks to Oct 20, 2026, shown 30 days after publication (the free analysts’ calls 3 days after). The top‑ranked analysts’ calls are in Exent Gems. See all of the latest analyst upgrades and downgrades.

Do analysts get INSM right?

Of the 345 analyst price targets on INSM set from 2019 until a year ago, 70.4% were reached within 12 months (data to Oct 20, 2026), 1.8 points above the 68.6% hit rate of the median stock in Exent’s study of 794 stocks. Targets that were reached took a median of 78 days. The median target sat 44.0% above the share price on the day it was set.

Where analysts said INSM would be by now: a year ago, 12 analysts had a price target on INSM, and the median of their latest targets was $216.00. On Oct 20, 2026 INSM closed at $95.68, 55.7% below it.

70.4%of targets reached within 12 monthsMedian stock: 68.6%
78 daysmedian time to reach a target
−55.7%price now vs the median target set a year ago

How INSM moves after earnings

INSM beat the consensus earnings‑per‑share estimate in 3 of its last 12 quarterly reports, through the one on Aug 6, 2026, and the revenue estimate in 10 of 12. From the close before each report to the close after it, the stock moved 8.9% on average, up or down, against 6.8% for the average report across the 1,002 US stocks Exent tracks. It rose after 4 of the 12 reports. In 2 of the 3 beats the stock still fell.

3/12earnings beats
±8.9%average move per report
4/12reports followed by a rise
ReportEPS vs estimateRevenue vs estimateStock move
Aug 6, 2026−$0.06 vs −$0.67+7.6%+32.4%
May 7, 2026−$0.76 vs −$0.96+1.7%−26.1%
Feb 19, 2026−$1.54 vs −$1.07+14.1%+9.1%
Oct 30, 2025−$1.75 vs −$1.33+23.3%+13.6%
Aug 7, 2025−$1.70 vs −$1.30+3.2%−1.5%
May 8, 2025−$1.42 vs −$1.34+1.5%−4.7%
Feb 20, 2025−$1.32 vs −$1.17+2.3%−3.3%
Oct 31, 2024−$1.27 vs −$1.20+0.1%−2.8%

Reported earnings per share against the consensus estimate, revenue surprise in percent, and the stock’s price change over the two sessions around the report. How stocks move after earnings

Where INSM’s revenue comes from

In fiscal 2025 (the year to Dec 31, 2025), INSM’s largest reported region was the United States, with 74.7% of its $606.4 million revenue. By region: United States 74.7%; Non-US 25.3%.

By business, the largest segment was Reportable Segment, with 100.0% of $606.4 million revenue (+66.7% on the year before).

  • United States74.7%
  • Non-US25.3%

From INSM’s annual filings; segment growth compares fiscal 2025 with the year before. Regions are as each company reports them, so one company’s “Asia Pacific” is not another’s. China counts the regions a company reports as China, Greater China or Hong Kong; a separately reported Taiwan is not counted. Which S&P 500 companies depend most on China?

Members of Congress who traded INSM

As of Oct 20, 2026, 2 members of Congress had disclosed 10 trades in INSM (2 buys and 8 sales) in STOCK Act disclosures filed with the House and Senate. The latest public trade is dated Jun 10, 2026.

Trade dateMemberTypeAmount
Jun 10, 2026Josh GottheimerSale$1,001–$15,000
Oct 3, 2025Gilbert CisnerosSale$1,001–$15,000
Sep 22, 2025Gilbert CisnerosSale$1,001–$15,000
Aug 8, 2025Gilbert CisnerosSale$1,001–$15,000
Jul 7, 2025Gilbert CisnerosSale$1,001–$15,000
Jun 16, 2025Josh GottheimerBuy$1,001–$15,000
Apr 9, 2025Josh GottheimerSale$1,001–$15,000
Jun 21, 2024Josh GottheimerSale$1,001–$15,000
May 28, 2024Josh GottheimerSale$1,001–$15,000
Dec 6, 2022Josh GottheimerBuy$1,001–$15,000

Amounts are the ranges members report, not exact values. The STOCK Act gives members up to 45 days to disclose a trade, so trades appear weeks after they are made. See every member’s disclosed trades

Are INSM insiders buying or selling?

In the 12 months to Oct 20, 2026, INSM insiders made no open‑market purchases and 169 sales, according to SEC Form 4 filings. The last open‑market purchase on record was on May 21, 2025.

After the 32 insider purchases of $10,000 or more since 2012, INSM beat the S&P 500 by an average of 87.8 percentage points over the next 12 months; 84% of them were followed by a beat. Across all 17,865 insider purchases in Exent’s study, the average was +17.2% and the median +1.0% against the index.

Q4 ’24
Q1 ’25
Q2 ’25
Q3 ’25
Q4 ’25
Q1 ’26
Q2 ’26
Q3 ’26
DateInsiderRoleValue
May 21, 2025Desjardins ClarissaDirector$74,976
May 20, 2025Desjardins ClarissaDirector$126,719
May 15, 2023Sharoky Melvin MdDirector$192,900
Nov 1, 2022Sharoky Melvin MdDirector$177,000
Oct 31, 2022Sharoky Melvin MdDirector$350,600

The table lists the latest open‑market purchases on record, leaving out the last 30 days. The chart counts Form 4 purchases and sales by calendar quarter. Purchases are open‑market buys; sales include planned sales under 10b5‑1 trading plans. Do insider buys beat the market?

How much of INSM is sold short?

As of the Sep 30, 2026 settlement date, 6.41% of INSM’s float was sold short: 13.8 million shares, or 6.5 days of average trading volume to cover. A year earlier (Oct 15, 2025) it was 4.41%. The median across the 997 US stocks Exent tracks was 4.77%, so INSM is more heavily shorted than most.

  • Apr 30, 20266.84%
  • May 29, 20268.89%
  • Jun 30, 20267.45%
  • Jul 31, 20265.28%
  • Aug 31, 20265.32%
  • Sep 30, 20266.41%

From FINRA short‑interest reports, filed twice a month; the bars show the short share of the float at each month‑end. Days to cover divides the shares short by the average daily volume. The most shorted stocks

How many institutions own INSM?

At the end of Q2 2026 (Jun 30, 2026), 718 institutions reported holding INSM in 13F filings, up 8 from the quarter before and up from 564 a year earlier. Their reported holdings add up to 104.4% of INSM’s shares. In the quarter 359 institutions added to their positions and 242 cut them.

71813F holders
114new positions
122positions closed
104.4%of shares held by 13F filers

Investment managers with over $100 million in US equities file 13F reports within 45 days of each quarter end, so this is the latest complete quarter. Holdings can add up to more than 100% when shares are lent and counted twice. Which stocks institutions are buying and selling

Is INSM diluting shareholders?

INSM’s diluted share count rose 118.9% over the five fiscal years to fiscal 2025 and rose 30.2% in fiscal 2025 alone. Each share now owns a smaller slice of the company. The median change across the 1,005 US stocks Exent tracks was −0.1%.

Stock‑based compensation was $152.7 million in fiscal 2025, 25.2% of revenue. INSM did not buy back shares in fiscal 2025.

+30.2%share count, 1 year
+118.9%share count, 5 years
25.2%stock pay as % of revenue
0.00%buyback yield

Weighted‑average diluted shares from INSM’s annual income statements; stock‑based compensation and buybacks from its cash‑flow statement. Stock dilution and stock‑based compensation, explained

INSM financial health scores

In Exent’s Oct 20, 2026 snapshot, INSM’s Altman Z‑score was 5.39, in the safe zone (where 465 of the 794 non‑financial US stocks Exent tracks sit). Its Piotroski F‑score was 4 out of 9; 88% of scored stocks reach 4 or more.

5.39Altman Z‑score: safe zone
4/9Piotroski F‑score

The Altman Z‑score combines five balance‑sheet and earnings ratios into one bankruptcy‑risk score: below 1.81 is the distress zone, 1.81–2.99 grey, above 2.99 safe. It is not meaningful for banks, insurers and REITs. The Piotroski F‑score counts nine yes/no tests of profitability, leverage and efficiency; 8–9 is strong, 0–2 weak. Both come from the latest annual statements. Which stocks have the highest bankruptcy risk?

Which ETFs hold INSM?

As of Oct 20, 2026, 30 of the 304 ETFs Exent tracks held INSM. Its largest weight is in XBI (State Street SPDR S&P Biotech ETF), at 1.13% of the fund.

ETFFundWeight of INSM
XBIState Street SPDR S&P Biotech ETF1.13%
IWPiShares Russell Mid-Cap Growth ETF0.61%
FXHFirst Trust Health Care AlphaDEX Fund0.37%
VBKVanguard Small-Cap Growth Index Fund ETF Shares0.36%
VHTVanguard Health Care Index Fund ETF Shares0.34%
VXFVanguard Extended Market Index Fund ETF Shares0.30%
VOTVanguard Mid-Cap Growth Index Fund0.29%
CGGRCapital Group Growth ETF0.21%

Owning several of these funds stacks the same position. How much do VOO, QQQ and VTI overlap?

The right benchmark for INSM

Exent matches every holding to the index with the most similar risk. For INSM that is SPY (the S&P 500). Comparing a holding with an index that carries very different risk makes good results look bad and risky ones look clever. Read why the S&P 500 is the wrong benchmark for most portfolios.

Other healthcare stocks

TickerName5‑year returnVolatility (5y)
LLYEli Lilly and Company+482.3%32.6%
JNJJohnson & Johnson+92.9%16.8%
ABBVAbbVie Inc.+207.1%23.5%
STESTERIS plc+2.0%25.8%
GHGuardant Health, Inc.+53.1%67.6%
VTRSViatris Inc.+75.8%33.8%
INCYIncyte Corporation+79.7%29.2%
THCTenet Healthcare Corporation+281.3%45.0%

Data and methodology

Returns are total returns from month‑end adjusted closing prices (dividends reinvested) through Oct 30, 2026. Crisis drawdowns and trailing maximum drawdowns use daily prices. Analyst coverage counts ratings published in the last 12 months, shown with a 30‑day delay. Full method: Exent methodology.

Company data as of Oct 20, 2026. The move around an earnings report runs from the close before it to the close after it; a price target counts as hit when the stock closed at or beyond it within 12 months (Exent analyst data). Revenue by region and segment, share counts and executive pay come from company filings; insider trades from SEC Form 4, short interest from FINRA, institutional ownership from 13F filings, Congress trades from STOCK Act disclosures filed with the House and Senate, federal contracts from USAspending.gov. Filings from the last 30 days are shown as counts only.

Past performance does not guarantee future results. Historical figures are calculated by Exent from market data and are for education only; they are not investment advice or a recommendation to buy or sell any security.

Check INSM with Exent Gems

Wall Street’s average INSM price target is 59.5% above the latest share price. See what the best‑ranked analysts on INSM say now in Exent Gems.

  1. Exent ranks Wall Street analysts by their past price‑target hit rate and returns, and keeps the best‑ranked few.
  2. Gems shows who the top‑ranked analysts covering INSM are, their live calls and the median target of only the top‑rated analysts.
  3. Gems flags the stocks where several top‑ranked analysts agree: a starting point for your own research, not a promise.

Exent is our product. Educational content, not investment advice.

Frequently asked questions

Yes. INSM returned +767.3% (+24.1% a year) over the 10 years to Oct 30, 2026, versus +316.3% (+15.3% a year) for the S&P 500, including dividends.

No. As of Oct 20, 2026, INSM (Insmed Incorporated) is not one of the 503 stocks in the S&P 500.

No. As of Oct 20, 2026, INSM (Insmed Incorporated) is not one of the 101 stocks in the Nasdaq-100.

INSM fell −66.4% from peak to trough during the global financial crisis (2007–09), versus −56.5% for the S&P 500.

INSM fell −56.4% from peak to trough during the covid crash (feb–mar 2020), versus −34.1% for the S&P 500.

INSM fell −39.3% from peak to trough during the 2022 inflation bear market, versus −25.4% for the S&P 500.

Over the 5 years to Oct 30, 2026, INSM’s Sharpe ratio was 0.58 and its Sortino ratio 1.60, versus 0.58 and 0.91 for the S&P 500.

INSM’s 5‑year annualized volatility was 60.5%, higher than the S&P 500’s 17.0%, with a beta of 0.84.

Among large US stocks, the lowest correlations with INSM over the last 60 months were MNST (−0.17), FTNT (−0.15), LMT (−0.13). Its correlation with long Treasuries (TLT) was 0.30 and with gold (GLD) 0.06.

INSM beat the consensus earnings-per-share estimate in 3 of its last 12 quarterly reports through Aug 6, 2026, and the revenue estimate in 10 of 12. The stock moved 8.9% on average, up or down, from the close before each report to the close after it.

Yes. As of Oct 20, 2026, 2 members of Congress had disclosed 10 trades in INSM (2 buys and 8 sales) in STOCK Act disclosures filed with the House and Senate.

As of the Sep 30, 2026 settlement date, 6.41% of INSM’s float was sold short (13.8 million shares, 6.5 days to cover), according to FINRA short-interest reports. A year earlier it was 4.41%.

Yes. INSM’s diluted share count rose 118.9% over the five fiscal years to fiscal 2025 and rose 30.2% in the latest year. Stock-based compensation was 25.2% of revenue.

What do the best‑ranked analysts say on INSM now?

Exent ranks Wall Street analysts by their track record. Gems shows who the top‑ranked analysts on INSM are, their latest calls and the stocks where several of them agree.

See this week’s GemsLimited offer$1.95 for full access· full access

Educational content, not investment advice. Examples are illustrative; past performance does not guarantee future results.

DISCLAIMER: Exent AI is an informational research platform and does not provide investment advice, financial advice, or act as an investment adviser, broker-dealer, or fiduciary. All content, analytics, and model outputs are provided for educational and informational purposes only and should not be relied upon as a recommendation to buy, sell, or hold any financial instrument. Investing involves risk, including the possible loss of principal. Exent AI does not execute trades, hold customer funds, or provide brokerage services. Past performance and hypothetical results are not indicative of future results. Third-party data and AI-generated outputs may be incomplete or inaccurate.